Drug Trial Radar · NCT06240546
First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Mar 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
102
Planned (sponsor's estimate)
Start
Mar 12, 2024
Primary completion
Feb 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Luye Pharma Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase 1, first-in-human, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability, pharmacokinetics characteristics and preliminary anti-tumor activity of LPM6690176 capsules in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
LPM6690176Drug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of dose-limiting toxicities (DLTs)Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)
- maximum tolerated dose (MTD) of LPM6690176Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.